Multiple myeloma – New publication in Leukemia

An adhesion molecule on multiple myeloma cells correlates with patient outcome and proves as a promising new target for cancer therapy. Today, the respected journal Leukemia published our new research article on JAM-A by lead authors Antonio Solimando and Andreas Brandl.
Publication Leukemia 2017 Junctional-adhesion-molecule 1, JAM-A, multiple myeloma, Andreas Beilhack, Antonio Solimando, Andreas Brandl

Our new study revealed that JAM-A expression correlates significantly with disease outcome in multiple myeloma patients. Targeting of JAM-A impacts cardinal features of cancer, such as multiple myeloma cell survival, progression and metastasis.

Read more about this new research publication.

 

Solimando AG*, Brandl A*, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stühmer T, Mokhtari Z, Rudelius M, Dotterweich J, Bittrich M, Desanti V, Ebert R, Trerotoli P, Frassanito MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A. (2017). JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia (advance online publication 24 October 2017) doi: 10.1038/leu.2017.287

*These authors contributed equally to this work.